Do you see any chance that if P3 holistically fails, the drug could still get approved for a more limited clinical approach, like PCV or occult? In footy terms, if P3 doesn’t kick a goal, could we at least get a point instead of being out of bounds on the full? What do you think?
- Forums
- ASX - By Stock
- OPT
- Opthea Q and A
Opthea Q and A, page-41
-
-
- There are more pages in this discussion • 6 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add OPT (ASX) to my watchlist
(20min delay)
|
|||||
Last
82.5¢ |
Change
0.015(1.85%) |
Mkt cap ! $1.015B |
Open | High | Low | Value | Volume |
84.5¢ | 84.5¢ | 80.0¢ | $2.835M | 3.473M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 17359 | 82.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
83.0¢ | 106026 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 17359 | 0.825 |
3 | 400620 | 0.820 |
1 | 1825 | 0.815 |
1 | 36026 | 0.810 |
5 | 42028 | 0.805 |
Price($) | Vol. | No. |
---|---|---|
0.830 | 106026 | 2 |
0.835 | 90127 | 3 |
0.840 | 94966 | 5 |
0.845 | 37266 | 2 |
0.850 | 102500 | 2 |
Last trade - 16.10pm 03/10/2024 (20 minute delay) ? |
Featured News
OPT (ASX) Chart |